Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics Holdings Plc LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.00 -2.22% 44.00 43.70 44.30 44.40 43.80 44.00 1,157,157 16:35:28
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 81.8 21.4 3.5 12.7 200

Ekf Diagnostics Share Discussion Threads

Showing 3901 to 3923 of 4525 messages
Chat Pages: Latest  157  156  155  154  153  152  151  150  149  148  147  146  Older
DateSubjectAuthorDiscuss
05/10/2021
09:36
Fact 1. Ekf struggled since the Pfizer vaccine news came out last Nov. Stock topped out 12 months ago. Goes to show that the market has discounted all covid related benefits to the business. Fact 2. When the news is bullish but the share price goes the other way, it is (always has been) an ominous sign foe those willing to listen.
tongosti
05/10/2021
09:12
Actually I think the comment before was EKF's inability to break through 80p. I have no doubt there will be future comment about the struggle to get through 90p. Goodness knows the fight we will have at 100p!

My strategy is to continue to hold EKF and continue to filter TONG

melody9999
05/10/2021
09:04
People who follow squiggly lines obsess about such things. It's normal.
jacks13
05/10/2021
08:24
Whist I don't support every utterance from Tongosti (his Mr Market obsession does get a little wearing) I think he does have a point about EKF's inability to break above 85
given the 100% positive newsflow and results. Perhaps the market is concerned that the Covid-driven testing bonanza won't be there forever and that the core business will take some years to fill the void?
CD

cambridgedon
05/10/2021
08:23
Obviously Luke's move from Longhorn was agreed by both companies. You don't poach people from one of your key customers. But can anyone give me an insight as to why this might have happened now - what is the bogger agenda behind this appointment wrt EKF and Longhorn?
melody9999
05/10/2021
07:55
What an insightful comment re a lifeless stock.
tongosti
05/10/2021
07:50
What nonsense this troll continues to spout. I'm up 45% over the past 14 months here plus a 3.8% dividend yield during that time. I have other stocks that have performed better and some that have performed worse. I'm happy with the performance here to date, particularly whilst during that period the idiotic tongosti troll has just completely wasted his time sniping from the sidelines and making zilch !
masurenguy
05/10/2021
07:33
Breakout firmly cancelled folks. Oops.

Question is: if this stock produced absolutely nothing during a wider bull market over the last 12 months, what can it do if markets turn firmly south? Well, we do know the answer to this one don’t we (not asking you mg - i am aware you have the ability to stay in all the way south)?!

tongosti
01/10/2021
13:05
Isn't that exactly the same message the market has been telling you folks for 12 months now? Lol
tongosti
01/10/2021
12:59
Agrees too much focus on short term covid solutions.
sirshagalot
01/10/2021
12:56
JESREDBIRD...All points of view/opinion are welcome. EKF make it quite clear in my view (beyond revealing sensitive plans/information etc) -

"While the growth of ADL Health has been accelerated by revenue from COVID testing, its wider testing offer, including current and planned capabilities, is considered by the EKF Board to provide an attractive platform to both complement and broaden the Group’s existing diagnostics capabilities."

On the one hand you are saying you are not impressed about expanding lab capacity, and on the other you then say you are interested in their roadmap to replace COVID-19, which would obviously involve expansion of what they currently offer.

However, I am sure that EKF's diagnostic pipeline will no doubt make for interesting reading! So, yes a key point is what EKF are 'planning' for and there are pointers within the release and indeed EKF's growth strategy. Not to mention that in an answer to one of my questions, a potential screening test for IBD, which as the growth strategy indicates, a CLIA lab for diagnostics is identified as one of the growth areas in terms of complementary earnings-enhancing acquisitions with key strategic value to the core business, for the following reasons -

CLIA lab for diagnostic tests
– Further area of partnership with global private sector partner
– Potential to link to Trellus, Renalytix and Verici
– Move into $4bn US diagnostic testing market which has forecast CAGR of 13% from 2021 to 2027

And indeed, in the EKF/ADL release it also states other important factors, cue a 'broader range of healthcare applications' and a testing offering that our industry 'partners' have been looking for us to provide -

'In addition, ADL Health is expanding its range of testing capabilities across a broader suite of healthcare applications. Under EKF’s ownership, further investment is anticipated to support the deployment of additional equipment and a testing offering that our industry partners have been looking for us to provide

Mike Salter - "Strategically this is an excellent move for us as it positions EKF as a leading provider of diagnostic products and services, including a testing offering that our industry partners have been looking for us to provide."

The above aside, I note a recent comment in reaction to the EKF's ADL acquisition:

Chris Helm, Executive Vice President Global Business Development at Longhorn Vaccines and Diagnostics
"Longhorn Vaccines and Diagnostics looks forward to continuing supplying PrimeStore MTM and ATM to ADL Health via our relationship with EKF Diagnostics. Congratulations to Mike and team"

I was also pleased to note that ADL appears to have been using ATM, which is currently for 'research use only'.

wan
01/10/2021
11:54
I don’t seem to be as impressed about the ADL purchase. Looking at their website, it really only appears that they provide COVID-19 testing. The fact that they have positive revenue is more a function of the pandemic than anything. Kind of like having a hose and selling water in front a burning house. I’m also not terribly impressed about “expanding lab capacity.” Being in the laboratory space, this is a commodity. My question is, what do they have on their roadmap to replace COVID-19 when test volume ebbs? It’s a very different thing to establish sales and distribution for molecular test outside of Covid. I like the terms of the deal on EKF’s behalf because it seems to be heavily weighted on the back end. To me, this recognizes the fact that ADL is really a one trick pony at this point.

My guess is that EKF wants a footprint in the US for molecular testing that compliments their point of care. If 10 million up front gets that done, and revenue beyond COVID is baked into the milestones, then it’s a fair price.

jsredbird
01/10/2021
08:24
For readers interest, Luke Daum, EKF Chief Scientific Officer, related patent and patent applications etc (where several are particularly notable) -

https://worldwide.espacenet.com/searchResults?submitted=true&locale=en_EP&DB=EPODOC&ST=advanced&TI=&AB=&PN=&AP=&PR=&PD=&PA=&IN=luke+daum&CPC=&IC=&Submit=Search

wan
01/10/2021
06:21
Increased volumes of MTM required to ramp lab testing volumes, future virus/preparedness, and to help address the upcoming flu season -

Jeff Fischer, President of Longhorn Vaccines and Diagnostics -"By combining our PrimeStore MTM liquid with SiO2's 12 millimeter test tube, labs have the ability to test a patient for multiple viruses—one tube can be used to test a patient for COVID-19, influenza A, and influenza B at the same time."

Longhorn Vaccines & Diagnostics and SiO2 Materials Science Team Up to Develop 12 Millimeter Sample Transport Media for Higher Volumes of Automated Virus Testing
September 30, 2021

AUBURN, Ala., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Longhorn Vaccines & Diagnostics, an innovative molecular tool, assay and vaccine development company focused on serving unmet critical needs in both developed and developing nations, and SiO2 Materials Science, a privately-owned U.S. advanced materials science corporation introducing breakthrough disruptive technology for packaging biological pharmaceuticals and vaccines, today announced a partnership to produce and distribute PrimeStore MTM in SIO2's proprietary 12 millimeter sample transport tubes. The transport tubes will allow large laboratories with high volumes of sample testing to pool 10 times more samples with 1/10th of the required materials. The sample transport tubes are manufactured by SiO2 and are available now to labs for testing COVID-19, influenza, and other widespread viruses.

Throughout the COVID-19 pandemic virus testing has been critical to targeting new cases and assessing the impact of the virus on the global population, and has inspired labs to shift towards higher volumes of testing for both COVID-19 and future virus needs. To further support this trend, the collaboration between Longhorn and SiO2 combines SiO2's 12 millimeter test tube with Longhorn's PrimeStore MTM, which is a patented, FDA-cleared sample collection system that inactivates RNA, mRNA, and DNA pathogens.

"We take immense pride in our partnerships, and our collaboration with SiO2 is no different—our companies have come together to meet the needs of virus testing today and prepare for the next pandemic. Si02's production capabilities are a key reason why we're working with them; they have the ability to produce millions of tubes per month," said Jeff Fischer, President of Longhorn Vaccines and Diagnostics. "By combining our PrimeStore MTM liquid with SiO2's 12 millimeter test tube, labs have the ability to test a patient for multiple viruses—one tube can be used to test a patient for COVID-19, influenza A, and influenza B at the same time."

Beyond the ability to test multiple viruses using one tube, labs can use the test results to subtype each virus and see which strains of COVID-19, influenza, respiratory syncytial virus, and other viruses are circulating within a specific population. This will allow the U.S. government to track viral patterns to dispatch appropriate testing and virus prevention.

"We reached out to Longhorn in February because we view their sample collection technology as first-in-class when it comes to inactive sample testing. With the availability of the COVID-19 vaccine, now is the time for us to join together to offer a new solution for virus testing at high volumes," said Lawrence Ganti, President and Chief Business Officer at SiO2 Materials Science. "We can produce up to two and a half million tubes per week, so combining our manufacturing with Longhorn's technology makes sense for the future of virus testing."

Longhorn was able to scale its operations from 50,000 to 100,000 tubes of PrimeStoreMTM per month prior to March 2020, to weekly shipment exceeding 2 million tubes during the height of COVID-19 in the US, to help the federal government expand its testing capabilities.

hTTps://www.globenewswire.com/news-release/2021/09/30/2306725/0/en/Longhorn-Vaccines-Diagnostics-and-SiO2-Materials-Science-Team-Up-to-Develop-12-Millimeter-Sample-Transport-Media-for-Higher-Volumes-of-Automated-Virus-Testing.html

wan
01/10/2021
04:53
Luke Daum - inventor of PrimeStore® MTM - joins EKF Diagnostics as Chief Scientific Officer

30th September 2021

EKF Diagnostics, the global in vitro diagnostics company, has appointed Luke Daum PhD as Chief Scientific Officer (CSO), bringing a wealth of expertise in molecular-based diagnostics to EKF’s leadership team. Inventor of the PrimeStore┬« MTM (Molecular Transport Medium), the FDA cleared and CE IVD marked sample collection device which deactivates viruses, Dr Daum holds significant industry experience in leading teams from concept to blockbuster products. In the fight against COVID-19, over 50 million PrimeStore MTM vials have now been distributed globally, supporting safe and reliable molecular testing.

In his role as Chief Scientific Officer at EKF Diagnostics, Dr Daum will provide a valuable scientific lead for the research and development of EKF’s broad clinical diagnostics product portfolio and support the Company’s growth of its molecular diagnostics and life science offering. “The future of EKF’s expansion into products and services that enhance diagnostic disease detection is very exciting, and I look forward to using my experience to help advance EKF’s growth into high throughput diagnostic testing centers, clinics, and at point-of-care,” said Dr Daum.

EKF’s incoming Chief Executive Officer, Mike Salter commented, “We are delighted to welcome Dr Luke Daum to EKF’s leadership team as a highly respected and liked member of the Life Science and Diagnostic community. His extensive knowledge and experience in successful product development and insights in molecular diagnostics will be instrumental as we continue to drive the significant momentum that we have realized in support of the COVID-19 pandemic response.”

Mike Salter’s appointment as CEO will be effective from 1 October 2021. As the current President of EKF Diagnostics’ American business, he has been responsible for all US facilities including sales, operations and Regulatory Affairs, and also has a particular focus on EKF Life Sciences in Elkhart, Indiana. Previously, Mike worked at GE Healthcare where he was General Manager for the Custom Molecular Reagent Business within GE Life Sciences.

Full release - hTTps://www.ekfdiagnostics.com/luke-daum-as-chief-scientific-officer.html

wan
30/9/2021
07:15
Edits to the above post
wan
30/9/2021
07:12
A factor that I was particularly impressed with is the ADL lab capacity as exemplified by their corporate offering of being capable of undertaking testing whether you have 10 employees or 10,000. Again as exemplified by already providing testing needs for dozens of Fortune 500 companies and government agencies.

And what also particularly piqued my interest was that ADL is expanding its range of testing capabilities across a broader suite of healthcare applications. Further augmented by EKF investment, cue Mike Salters comment -

“The ability to offer testing for a wide range of diseases, combined with our existing point-of-care device, reagent, sample collection, kitting and manufacturing services, positions us as a single provider able to encompass all products and services from ‘sample-to-result’.

And indeed the roll of EKF's new Chief Scientific Officer, Luke Daum. Who recently commented as a reaction to the ADL acquisition, that he was "Excited to be part of EKF’s exponential molecular biology growth!

wan
30/9/2021
06:36
Simple and clear:

https://www.adlhealth.com/

mirandaj
28/9/2021
14:08
Relative strength through the roof. Good this happens during tumultuous wider market conditions. I couldn't care less what fundamentals suggest unless the share price plays ball. Been v quiet post b/o day (except today) but somehow this has still held its nerve. This is then only uk stock I have a position in at the moment so who knows this maybe indeed about to travel North soon (or not in which case the good old SL is the best insurance policy).
tongosti
28/9/2021
12:53
Interesting. I specifically asked about this element of the company’s strategy at the recent results presentation and it was acknowledged that this would constitute a step change for EKF. I note that ADL was only established last year, although it’s backers have been around a lot longer. It sounds as if EKF intends to invest a good deal more, so no doubt we can expect further announcements, including key customer contracts. One thing I am not clear about is what sort of employee base ADL has and whether its founders will have any ongoing role, other than as shareholders for a period.
james188
28/9/2021
09:03
Melody...Indeed!
wan
28/9/2021
08:58
Wan - yeah I get that. If I was selling my business, I'd want some cash in my bank account please. Unless of course I was super super confident that all that cash would be better off in the shares of my acquirer.
melody9999
28/9/2021
08:51
Melody9999...Duly noted, but my read into that is that EKF is very confident about their own prospects, including the growth strategy, and indeed their own cash generation.
wan
Chat Pages: Latest  157  156  155  154  153  152  151  150  149  148  147  146  Older
Your Recent History
LSE
EKF
Ekf Diagno..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20221206 01:56:16